Study drug to reduce LDL cholesterol effects in heavy drinkers
Treatments studied
Part of Digestive system clinical trials.
This Phase 1 study tests how safe a cholesterol-lowering antibody (alirocumab) is in people who drink heavily but are not seeking alcohol treatment. It also looks at early drug effects in the body to see how it might change cholesterol-related signals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 21 and 65 years old.
- You can sign an informed consent form.
- You are a heavy drinker (about 20+ standard drinks per week for at least 12 weeks) and are not in alcohol treatment.
- If you can get pregnant: you must have a negative pregnancy test, not breastfeed, and use approved birth control or abstain.
- You must not have a history of serious allergic reactions to PCSK9 medicines (like alirocumab) or similar antibodies.
- You likely must have stable key health tests (liver/kidney/diabetes/cholesterol) and no major uncontrolled illness.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
This study tests whether a cholesterol-lowering injection (alirocumab) helps people who are on regular dialysis. It aims to improve cholesterol control in a carefully selected group and tracks safety during treatment.
This study tests an experimental drug (QLC7401) that may help lower LDL ('bad') cholesterol in people who already have high cholesterol or mixed hyperlipidemia. If you're on stable cholesterol medication but still need more lowering, this trial could offer another option.
This trial tests whether giving a cholesterol-lowering injection (called a PCSK9 inhibitor) early after a stroke helps improve recovery and lowers cholesterol. It is for people whose stroke is caused by narrowed arteries, not by heart problems.
This study tests an educational program to help people understand and lower their LDL ('bad') cholesterol after a heart-related event. It aims to improve awareness and encourage the use of cholesterol-lowering treatments.
This study tests a new investigational medicine (QLC7401) that aims to lower LDL ('bad') cholesterol when added to your current cholesterol-lowering therapy. If you are already on a statin but your cholesterol is still not low enough, this trial might help you reach your goals.
Hear when a new Alcohol-associated Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.